Emerging Company Profile
Interius design: Penn spinout gets specific with in vivo CAR Ts
Emerging Company Profile: Philadelphia cell and gene therapy play has $76M from Cormorant, Fairmount to get to clinic
With $76 million in a series A funding, Penn spinout Interius is developing in vivo CAR Ts for hematologic cancers.
Cell and gene therapy company Interius has $76 million from a series A funding led by Bihua Chen’s Cormorant and Fairmount and the guidance of Executive Chairman Lonnie Moulder to develop an in vivo CAR T technology spun out of the University of Pennsylvania that the company says gives it the specificity it needs to deliver genetic payload